Methylmalonic acidemia

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

Retrieved on: 
Thursday, August 17, 2023

WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • As part of this initiative, the Company plans to:
    Continue to Advance SEL-212 in Patients with Chronic Refractory Gout in Partnership with Sobi.
  • The decrease was primarily the result of the capital prioritization initiative that was enacted in the second quarter of 2023.
  • Net (Loss) Income: For the second quarter of 2023, Selecta reported net loss of $11.4 million, or basic net loss per share of $(0.07).
  • Selecta’s management will host a conference call at 8:30 AM ET today to provide a corporate update and review the Company’s second quarter 2023 financial results and strategic updates.

Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma

Retrieved on: 
Wednesday, July 12, 2023

ABU DHABI, United Arab Emirates and PALO ALTO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Burjeel Holdings, one of the largest healthcare providers in the MENA region, and BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, have announced a new project to revolutionize the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region. The two entities signed a preliminary, non-binding Collaboration Agreement establishing a mutual intention to work together on project ‘NADER’ (Needs Assessment and Therapeutics Development for Rare Diseases – ‘nader’ meaning ‘rare’ in Arabic). Genetic in origin, these often life-threatening or chronically debilitating diseases affect a small percentage of the population and are present throughout the person's entire life, even if symptoms do not immediately appear. The partnership will launch operations in Abu Dhabi to conduct clinical trials and research, leveraging the Emirate’s advanced infrastructure for innovation and life science.

Key Points: 
  • The partnership will launch operations in Abu Dhabi to conduct clinical trials and research, leveraging the Emirate’s advanced infrastructure for innovation and life science.
  • Project ‘NADER’ aims to revolutionize the field of early diagnosis and treatment in order to potentially improve patient outcomes.
  • Dr. Khaled Musallam, Group Chief Research Officer of Burjeel Holdings and project lead said, “Many rare diseases are highly clustered in our region due to our unique genetic pool.
  • As the collaboration unfolds, both Burjeel Holdings and BridgeBio anticipate significant progress in the field of rare diseases in the region.

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 4, 2023

WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • As part of this initiative, the Company plans to:
    Advance SEL-212 in Patients with Chronic Refractory Gout in Partnership with Sobi.
  • In March 2023, Selecta and its SEL-212 development partner, Sobi, reported positive Phase 3 data from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials.
  • Collaboration and License Revenue: Revenue for the first quarter of 2023 was $5.9 million, as compared to $34.0 million for the same period in 2022.
  • Selecta’s management will host a conference call at 8:30 AM ET today to provide a corporate update and review the Company’s first quarter 2023 financial results and strategic initiatives.

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 19, 2023

ET

Key Points: 
  • ET
    BASEL, Switzerland, April 19, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today reported financial results and provided a business update for the full year ended December 31, 2022.
  • “2022 was a very good year for VectivBio as we made significant progress against our R&D and corporate objectives, despite the challenging biotech environment.
  • In November 2022, the Company announced the completion of enrollment of the Colon-in-Continuity (CIC) stratum of the Phase 3 STARS study.
  • The Company will discuss these results on a call today, April 19, 2023, at 8:00 a.m.

GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, April 13, 2023

Throughout 2022 GENFIT and Ipsen stepped up their collaboration in order to minimize the time to filing as well as prepare for the commercial launch next year, if approved.

Key Points: 
  • Throughout 2022 GENFIT and Ipsen stepped up their collaboration in order to minimize the time to filing as well as prepare for the commercial launch next year, if approved.
  • In September 2022, GENFIT acquired clinical-stage biopharmaceutical company Versantis based in Zurich (Switzerland), significantly expanding its pipeline.
  • Two Pipeline Days were organized in October 2022 in Paris and New York, to present these programs in detail.
  • In October 2022, GENFIT announced the development of NIS2+TM, a next-generation technology for the diagnosis of at-risk NASH, and the presentation of results on NIS2TM+’s clinical performance in three poster presentations at The Liver Meeting® 2022 organized by the AASLD2.

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 2, 2023

We look forward to the potential for SEL-212 to address the unmet needs of patients suffering from chronic refractory gout.

Key Points: 
  • We look forward to the potential for SEL-212 to address the unmet needs of patients suffering from chronic refractory gout.
  • In addition, we are currently enrolling patients in ReiMMAgine, our Phase 1/2 clinical trial of SEL-302 for the treatment of MMA.
  • Selecta believes its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into mid-2024.
  • Selecta’s management will host a conference call at 8:30 AM ET today to provide a corporate update and review the Company’s fourth quarter and full year 2022 financial results.

Selecta Biosciences Provides Business Update and Outlook for 2023

Retrieved on: 
Monday, January 9, 2023

The IL-2 candidate will be studied in combination with ImmTOR to further advance and expand the pipeline in autoimmune disease.

Key Points: 
  • The IL-2 candidate will be studied in combination with ImmTOR to further advance and expand the pipeline in autoimmune disease.
  • The Company plans to initiate IND enabling studies in 2023 while also exploring multiple autoimmune indications that would be suitable for study with ImmTOR-IL.
  • Selecta is responsible for the early development activities and manufacturing of Xork and will maintain the rights for the development of additional indications beyond Pompe disease.
  • DISSOLVE I & II trials are on track for joint topline data expected in Q1 2023.

CANbridge Consolidates Gene Therapy Portfolio

Retrieved on: 
Wednesday, January 4, 2023

Animal data presented in 2022 at the American Society of Gene and Cell Therapy (ASGCT), the European Society of Gene and Cell Therapy (ESGCT) and the World Muscle Congress, showed that the gene therapy outperformed the benchmark therapy along multiple key endpoints in a mouse model of SMA and exhibited much less liver toxicity when administered intravenously.

Key Points: 
  • Animal data presented in 2022 at the American Society of Gene and Cell Therapy (ASGCT), the European Society of Gene and Cell Therapy (ESGCT) and the World Muscle Congress, showed that the gene therapy outperformed the benchmark therapy along multiple key endpoints in a mouse model of SMA and exhibited much less liver toxicity when administered intravenously.
  • The benchmark therapy uses a vector similar to that used in the only gene therapy approved for SMA.
  • CANbridge sponsored the research and is evaluating the gene therapy to determine potential additional advantages over the current standard-of-care.
  • Under an amended agreement, CANbridge retains an exclusive worldwide license to the products in the Fabry and Pompe gene therapy programs that use the AAV sL65 liver targeting capsid.

Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

Retrieved on: 
Tuesday, October 11, 2022

These presentations demonstrate the therapeutic utility of Selectas immune tolerance platform, ImmTOR, to enable safe repeated vector doses and mitigate unwanted immune responses to AAV capsids.

Key Points: 
  • These presentations demonstrate the therapeutic utility of Selectas immune tolerance platform, ImmTOR, to enable safe repeated vector doses and mitigate unwanted immune responses to AAV capsids.
  • We are thrilled to present data demonstrating the power of ImmTOR combined with T-reg specific IL-2 mutein (ImmTOR-IL), said Dr.Kei Kishimoto, Ph.D., Chief Scientific Officer ofSelecta.
  • In parallel, we will continue our pioneering efforts to help gene therapy patients overcome immunogenicity.
  • The Company specifically disclaims any intention to update any forward-looking statements included in this press release except as required by law.

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

Retrieved on: 
Monday, June 13, 2022

WATERTOWN, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced several pipeline advancements and partnership updates.

Key Points: 
  • Additionally, Selecta is eligible to receive an additional $4 million payment upon the achievement of certain near-term preclinical milestones by Sarepta.
  • DISSOLVE II, the second of two Phase 3 clinical studies evaluating SEL-212 for chronic refractory gout, continues to progress.
  • The completion of enrollment in DISSOLVE I & II will result in a $10 million milestone payment obligation from Sobi to Selecta.
  • Selecta expects to start a Phase 1 clinical trial in Q4 2022.